The technology BBI have created provides users with a method of testing whatever location they are in, providing quantifiable results in an instant, removing much of the time and cost associated with conventional laboratory testing.
The Novarum technology is accessible on the majority of leading smartphones available in today’s market and can be easily downloaded by existing phones via app stores and Google Play.
Head of Sales at BBI, Leigh Thomas, commented that: “Every lateral flow test is unique; we have created a bespoke service which can provide users with instant and quantifiable results. The fact that the service can be customised to your specific lateral flow ensures a hand held reader that provides the specific results you need as and when you need them. The connectivity of the reader is also revolutionary and separates this from existing platforms.”
The development of the BBI Group over the years has seen the acquisition of Biozyme Laboratories and Seravac Biotec in 2007 and SCIPAC in 2010. This expansion has led to the creation of a portfolio of services which offer immunoassay manufacturers an end to end IVD assay development solution from concept through to launch.
The AACC 2012 takes place in Los Angeles, California from the 17th to the 19th of July. Visitors will be able to find BBInternational, BBI Enzymes and SCIPAC in the South Hall, at booth 627.
BBI is also inviting customers to join the company at this year’s Annual Meeting.
About BBI Holdings
BBI Holdings is an organisation comprised of BBInternational, BBI Enzymes, SCIPAC and BBI Healthcare, which can be found online at http://www.bbigold.com, http://www.bbienzymes.com, http://www.scipac.com, www.hypobox.com and www.hyposite.com respectively.
BBInternational is a leading global supplier and manufacturer of high quality gold reagents which are uased within lateral flow rapid diagnostic tests at the point of care (POC). Over the years BBInterational, with its own unique recipe gold colloid, has developed an enviable reputation as the supplier of choice in the global diagnostics marketplace.
BBI Enzymes was launched in 2009 and in just a short time has developed a global customer base of blue chip customers operating in the highly regulated diagnostic and pharmaceutical markets. The foundation of stringent adherence to internationally accredited policy procedures has led to high demand for BBI Enzymes’ range of products, which includes purified human antigens, matching antibodies, serum/plasma products, disease state and patient samples. The Company operates a quality management system which complies with the current requirements of BS EN ISO 9001 and has been registered with the British Standard Institute (BSI) since January 1993.
BBI Healthcare provides a range of fast acting glucose tablets as well as specialist women’s health products and a range of nutritional supplements both in the UK and abroad, with the aim of ‘making life easier’ for individuals who need to keep a careful eye on their health and wellbeing.